Nuclear Factor-κB Pathway–Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type  Lianne Koens, Willem H. Zoutman, Passorn Ngarmlertsirichai, Grzegorz K. Przybylski, Piotr Grabarczyk, Maarten H. Vermeer, Rein Willemze, Patty M. Jansen, Christian A. Schmidt, Cornelis P. Tensen  Journal of Investigative Dermatology  Volume 134, Issue 1, Pages 290-292 (January 2014) DOI: 10.1038/jid.2013.265 Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Pathway overview and genetic aberrancies in primary cutaneous large B-cell lymphoma, leg type. The suggested relations between the different components of B-cell receptor signaling and MYD88 signaling are represented (Yang et al., 2012). The molecules affected by genetic aberrancies in PCLBCL-LT are indicated in red, and the percentages of cases affected by these aberrancies are indicated. Molecules that can be therapeutically targeted for inhibition of the NF-κB pathway are represented in green. Journal of Investigative Dermatology 2014 134, 290-292DOI: (10.1038/jid.2013.265) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions